Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by ...

Stock in the healthcare provider Humana came under pressure again on Friday after the U.S. government released quality ...

The U.S. government announced quality ratings for 2025 Medicare health and prescription drug plans on Thursday, the first ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

CVS risks losing customers and revenue if it splits up its vertically integrated business segments, which includes health ...

The layoffs are part of CVS’ plans, announced last week, for slashing 2,900 corporate jobs nationwide, as it seeks to cut $2 ...

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

From a valuation perspective, the stock is inexpensive, trading at a forward price-to-earnings (P/E) of about 8.4 times based ...

Barclays upgraded CVS Health Corp (NYSE:CVS) shares to Overweight from Equal Weight, citing a promising outlook for the company's margin recovery. The firm also raised its price target for CVS shares ...

About 40% of MA plans with prescription drug coverage will earn four or more stars, a dip from 42% this year, according to data released by the CMS.

Analyses of 2025 Medicare Advantage star ratings continue to pour in and not all of it bodes well for the conventional ...

CVS is reportedly conducting a strategic review and weighing options for separating some of the company’s businesses.